VaughnCBJakimovskiDKavakKS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol2019; 15(6): 329–342.
2.
AndrodiasGLünemannJDMaillartE, et al. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain2025; 148: 1459–1478.
3.
WeidemanAMTapia-MaltosMAJohnsonK, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol2017; 8: 577.
4.
Langer-GouldALiBHSmithJB, et al. Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm2024; 11(3): e200211.
5.
ProsperiniLHaggiagSTortorellaC, et al. Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression. Mult Scler2021; 27(9): 1391–1402.
6.
ProsperiniLHaggiagSRuggieriS, et al. Stopping disease-modifying treatments in multiple sclerosis: A systematic review and meta-analysis of real-world studies. CNS Drugs2023; 37(10): 915–927.
7.
CorboyJRFoxRJKisterI, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): A multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol2023; 22(7): 568–577.
8.
MouresanEFMentesidouEBerglundA, et al. Clinical characteristics and long-term outcomes of late-onset multiple sclerosis: A Swedish Nationwide Study. Neurology2024; 102: e208051.
9.
JouvenotGCourbonGLefortM, et al. High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS. JAMA Neurol2024; 81: 490–498.
10.
JutoAFinkKAl NimerF, et al. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord2020; 37: 101468.
